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Abstract--A substantial amount of data is available to suggest that lysosomal sequestration of amino- 
glycoside antibiotics plays a role in the pathogenesis of aminoglycoside-induced renal tubule cell injury; 
however, relatively little information is available on the subcellular distribution of aminoglycosides in 
the kidney during treatment protocols of the type that ultimately go on to produce extensive lethal renal 
tubule cell injury and acute renal failure in experimental animals. This study assessed the distribution 
of gentamicin and subcellular membranes on a discontinuous sucrose density gradient after in vivo 
exposure of rats to four daily 100 mg/kg doses of gentamicin as compared to in vitro exposure of normal 
rat renal cortex to gentamicin during tissue homogenization at drug levels comparable to those seen 
after in vivo treatment. After both in vivo and in vitro exposure, major localization of gentamicin, the 
lysosomal marker enzyme N-acetyl-fl-D-glucosaminidase (NAG), and the endoplasmic reticulum marker 
enzyme NADPH-cytochrome c reductase, occurred in a very light membrane fraction. Within this 
membrane fraction, gentamicin was more closely associated with the NAG than with the NADPH- 
cytochrome c reductase. The results could not be explained by complete lysosomal disruption during 
subcellular fractionation after in vivo gentamicin. These data provide additional insights into both the 
possibilities for subcellular interactions of aminoglycosides in the kidney, and into the methodology 
required to optimally assess such interactions. 
The recognition that a large fraction of the high levels 
of aminoglycoside antibiotics which accumulate in 
the renal cortex in treated patients and in animal 
models of aminoglycoside nephrotoxicity is seques- 
tered within lysosomes has been a major advance in 
the understanding of the pathogenesis of amino- 
glycoside-induced renal tubular cell injury. 
However, the most unequivocal data on subcellular 
distribution of aminoglycosides after prolonged 
courses of exposure have been obtained not in kidney 
or in a kidney-derived tissue model, but in cultured 
fibroblasts [1, 2]. Subcellular fractionation and auto- 
radiographic studies have indeed provided definitive 
evidence that lysosomal sequestration does occur 
in the kidney in v ivo  acutely after tracer doses of 
gentamicin [3-7], but little is known about the sub- 
cellular distribution of aminoglycosides during pro- 
longed courses of exposure of the type associated 
with significant nephrotoxicity [3, 8-10]. Such infor- 
mation is of substantial importance in assessing the 
relevance of extralysosomal versus lysosomal events 
in the pathogenesis of aminoglycoside-induced renal 
tubular cell injury and nephrotoxicity. In this regard, 
recent data have indicated that a number of promi- 
nent extralysosomal events are demonstrable in the 
early development of gentamicin-induced renal tubu- 
lar cell injury: (1) functional and structural defects 
are present in isolated mitochondria and brush bor- 
der membranes [3, 9-13], (2) acidic phospholipids 
are specific binding sites for the aminoglycoside on 
* Address correspondence to: Dr. J. M. Weinberg, 
Nephrology Division. D3238 MPB, Box 19, University of 
Michigan Medical Center, Ann Arbor, MI 48109. 
brush border membranes 111], and (3) amino- 
glycoside treatment appears to produce early alter- 
ations in the acidic phospholipid content of non- 
lysosomal cellular membranes [13]. 
Furthermore, in vitro gentamicin binding to a var- 
iety of subcellular membranes has been documented 
[3, 11, 14-16]. The present study was designed to 
obtain more information on the possible subcellular 
distribution of gentamicin in the kidney after an in 
v ivo  course of treatment of sufficient magnitude to 
result in substantial nephrotoxicity in the rat but at 
a time prior to the occurrence of advanced renal 
tubular cell injury and necrosis. Cellular frac- 
tionation techniques previously reported to be effec- 
tive in assessing the subcellular distribution of genta- 
micin in isolated fibroblasts [1, 2] and the subcellular 
distributions of cationic amphiphilic drugs which are 
concentrated in hepatic lysosomes were utilized [ 17- 
20]. 
MATERIALS AND METHODS 
Male Sprague-Dawley rats (Harlan) weighing 
275-300g and maintained on a standard lab diet 
(1% calcium) were used for all studies. Gentamicin 
treatment was with a single daily subcutaneous dose 
of 100mg/kg gentamicin as gentamicin sulfate 
(Sigma, St. Louis, MO) for 4 consecutive days. Rats 
were killed 24 hr after the last dose. 
Kidneys were rapidly removed and placed in ice- 
cold 0.27M sucrose. Then the cortices were 
dissected, minced and homogenized. For control (C) 
and in v ivo  gentamicin-treated (G) groups, the 
homogenizing solution consisted of 0.27 M sucrose, 
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40 ml cellulose acetate tube 
Beckman L3-50 Ultracentrifuge 
SW- 27 Rotor 
25,000 rpm x 150 minutes 
Fig. 1. Graphic summary of the discontinuous sucrose 
density gradient utilized. The subcellular fraction desi~ 
nations indicate areas of the gradient selected for detailed 
analysis in Tables 1 and 2. 
1 mM EGTA*, 5 mM Tris-HC[, pH 7.4. For control 
groups exposed to gentamicin in vitro during homo- 
genization, Tris-gentamicin (pH 7.4) was added to 
this homogenizing solution at a concentration esti- 
mated to approximate the level present after in vivo 
gentamicin treatment. The homogenate was spun at 
600g for 10min to remove nuclei and nonhom- 
ogenized cellular debris. 
For simultaneous subcellular fractionation into 
multiple membrane components, 10 ml of the 600 g 
postnuclear supernatant fraction was layered onto a 
discontinuous sucrose gradient in a 40 ml cellulose 
acetate tube, as illustrated in Fig. 1. The gradient 
was then centrifuged at 25,000 rpm using an SW-27 
rotor in a Beckman L3-50 ultracentrifuge. For some 
studies, samples of major regions of the gradient 
were taken carefully from the top of the tube with a 
pipetter; for others, the entire gradient was frac- 
tionated into 1-ml samples using a Gilson fraction 
collector. 
Activities of N-acetyl-fl-D-glucosaminidase 
(NAG), alkaline phosphatase, rotenone-insensitive 
NADPH-cytochrome c reductase, Na+-K+-ATPase 
and cytochrome oxidase were assayed as previously 
detailed [13]. 
Gentamicin levels were measured by RIA (New 
England Nuclear) on samples solubilized with 0.15% 
Triton X-100. 
Proteins were assayed by the method of Lowry et 
al. [21]. 
All reagents used were of the highest grade com- 
mercially available. All organic reagents were 
obtained from Sigma. 
Statistical tests utilized are detailed in Results. 
* Abbreviations: EGTA, ethylene glycol bis(/~amino- 
ethyl ether) N.NLtetraacetic acid; Tris, Tris(hydroxy- 
methyl)aminomethane), NAG. N-acetyl-~-D-giucosami- 
nidase; and NADPH. nicotinamide-adenine dinucleotide 
phosphate. 
RESULTS 
In the first series of experiments, gradients were 
sampled at several discrete points which preliminary 
studies had suggested would provide the best defini- 
tion of various subcellular membranes as identified 
by enzyme markers. Table 1 summarizes the results 
of these studies as regards enzyme composition of 
each fraction, predominant membranes present as 
deduced from the enzyme composition, and genta- 
miein level factored for mg protein. The G group 
had a mean +- S.E. homogenate gentamicin level 
of 8.8-+ 0.3 ug/mg protein while the homogenate 
gentamicin level of the C + G group was 
10.2 -~ 0.1 ug/mg protein, As can be seen in Table 
1, the major enrichment of gentamicin activity 
occurred in fraction 1 which was also enriched in the 
lysosomal marker, NAG, and in the endoplasmic 
reticulum marker, NADPH-cytochrome c reductase. 
Furthermore, both group G (in vivo gentamicin 
exposure) and group C + G (in vitro gentamicin 
exposure) exhibited generally similar patterns of 
gentamicin distribution on the gradient. 
The sampling methodology employed in the first 
series of gradient studies did not allow for assessment 
of extent of recovery of enzymes and gentamicin 
off the gradient and could have missed differences 
between closely adjacent areas, or in non-sampled 
areas. For this reason, another series of experiments 
was done using the same type of sucrose gradient 
and the same groups, C, G, and (7 + G but sampling 
the entire gradient in 1-ml atiquots and analyzing 
each for protein, enzyme activity, and gentamicin 
level. Recoveries for all parameters measured were 
85-110% of the amount layered on the gradients. 
The G group had a mean -+ S.K. homogenate genta- 
micin level of 7.6 + 0.6 l~g/mg protein while the hom- 
ogenate gentamicin level of the C + G group was 
8.4 -+ 0.3 yg/mg protein. Representative gradients 
from each group are illustrated in Fig. 2. As in 
the initial series of gradients, there were prominent 
localizations of NAG, NADPH-cytochrome c 
reductase and gentamicin to light membranes coming 
off in gradient fractions 10-19. This occurred simi- 
larly in the in vivo group (G) and in the in ~,itro 
group (C + G). 
To better quantify the average behaviors of mem- 
brane enzymes and gentamicin in this series of gradi- 
ents, the data were analyzed to determine the mean 
percent of total enzyme and gentamicin on the gradi- 
ent found in each gradient region. Based on enzyme 
characteristics, values for the l-ml aliquots were 
pooled to give results for gradient regions approxi- 
mately corresponding to the areas sampled in the 
first group of gradients (Table 1), However, in this 
series of gradients, no area remained unsampled, the 
identified regions are contiguous and cover the entire 
gradient, and a fraction rich in mitochondria (No. 5 
in Fig. 1) which was not sampled in the first series 
of gradients is reported. These data are summarized 
in Table 2. 
Somewhat more cvtochrome oxidase activity was 
present in the area defined as fraction 1 in the second 
series of gradients (,Table 2), but otherwise the over- 
all behavior of marker enzyme activity was similar 
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Fig. 2. Profiles of the distributions of protein, gentamicin and subcellular membrane associated cnzvmcs 
on representative gradients from a control rat (C), a rat treated with gentamicin in vivo (G), and a 
control rat whose renal cortex was homogenized in vitro with gentamicin present (C + G). Each bar 
indicates a single 1-ml aliquot of the gradient with fraction number 1 corresponding to the top of the 
gradient (S in Fig. 1) and fraction 40 being the bottom of the gradient. For each aliquot, the percent of 
total activity of the measured parameter found in it is graphed. Abbreviations: protein (Prot), N-acetvl- 
fi-D-glucosaminidase (NAG), alkaline phosphatase (AP), NADPH-cytochrome c reductase (Red), and 
gentamiein (Gent). 
evident  from Table  2 that, as in the first series of 
gradients, gentamicin preferential ly migrates in 
fraction 1 which also contains the most N A G  and 
N A D P H - c y t o c h r o m e  c reductase activities. 
Addit ional ly,  as was seen in the first series of experi- 
ments,  gentamicin behaved similarly in G (in vivo) 
and C + G (in vitro) groups. 
The analysis summarized in Table 2, however ,  
does not optimally quanti tate  the enzyme activity 
and gentamicin in the unsedimentable  cytosolic pro- 
tein fraction because particulate areas intermix vari- 
ably with the lower several milliliters of this area of 
the gradient.  To bet ter  assess the amount  of unsedi- 
mentable  activity without this confounding factor 
and, thereby,  to gain some estimate of whether  
changes in fragility of subcellular organelles after in 
vivo or in vitro gentamicin substantially affected the 
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Fig. 3. Unsedimentable enzyme and gentamicin activities. 
Values given are the mean percentages -+ S.E. of enzyme 
activity originally in the 600 g postnuclear supernatant frac- 
tion which remained in the supernatant layer of the gradient 
after centrifugation and which were, thus, unsedimentable. 
Details of how these values were calculated are given with 
the Results. G - in vivo gentamicin. C + O -  in vitro 
gentamicin. Statistically significant (P < 0.05 or better) dif- 
ferences by paired t-test are indicated as follows: (*) G vs 
control; (#) G vs C + G: and (+) control vs C + G. 
gentamicin in the first 5 ml of the gradient were 
multiplied by 2 in order  to extrapolate  to the 10 ml 
volume of 600g supernatant  fraction originally lay- 
ered on each gradient  so as to assess what fraction of 
each enzyme component  of the original postnuclear  
(600g) supernatant  fraction was nonsedimentable .  
These data were available for both types of gradient 
studies done and were pooled.  The results are 
summarized in Fig. 3. 
The percent  nonsedimentable  activity found in the 
supernatant  fraction was similar to that repor ted  in 
other  density gradient studies to the extent  that 
comparable  data are available [1,2, 17, 18]. Group 
G had slightly but significantly more nonsedi- 
mentable  protein than group C and groups G and 
C + G had more  nonsedimentable  N A G  than con- 
trols, suggesting the occurrence of some increased 
organellar  fragility with gentamicin,  but the dif- 
Table 3. Associations between gentamicin and membrane 
marker enzymes in gradient fraction 1" 
In vitro ht vioo 
Expt. No. NAG RED NAG RED 
1 [).882 0.320 [).824 0.342 
2 0.241 0.198 0.933 0,166 
3 [).914 0.201 0.924 0.182 
4 0.965 0.278 
Mean 0.679 0.240 0.912 [).242 
S.E 0.179 0.033 [).026 [).035 
* Correlation coefficients between levels of gentamicin 
and NAG and gentamicin and NADPH-cytochrome c 
reductase (RED) in the seven to nine l-ml fractions com- 
prising "'Fraction l'" of the sucrose density gradient after in 
vitro and in vit;o gcntamicin. 
ferences were small. UnsedimentabTe gentamicin 
was significantly higher in group C + G than in group 
G indicating that some constraints on redistribution 
of gentamicin after in vit, o t reatment ,  probably 
related to in tffvo sequestrat ion,  were retained during 
the separatory procedures.  
The second group of gradient studies in which 
all fractions were analyzed (Table 2) provided the 
opportuni ty to correlate levels of gentamicin with 
levels of N A G  and N A D P H - c y t o c h r o m e  c reductase 
within the 7---9 fractions comprising region 1 of the 
gradient,  the area of most prominent  gentamicin 
localization, to ascertain with which enzyme the 
gentamicin was most closely associated. These data 
are summarized in Table 3. They indicate that, after 
in t)ivo gentamicin,  an excellent correlation between 
gentamicin and N A G  activity was uniformly presenl 
while gentamicin correlated poorly with N A D P H -  
cytochrome c reductase activity. However ,  an ident- 
ical pattern of gentamicin distribution was seen after 
in vivo gentamicin in lwo of three experiments.  
DISCUSSION 
The past several years have witnessed a substantial 
increase in the understanding of the cellular patho- 
physiology of aminoglycoside nephrotoxicity.  Promi- 
nent among the advances in this area has been 
recognition of major  lysosomal effects of amino- 
glycosides in renal proximal tubule cells. Multiple 
observations indicate the importance of lysosomes 
in the effects of aminoglycosides on renal tubular 
cells. Morphologic  changes characterized by 
increases in lysosomal size and development  of 
myeloid bodies have been well documented and, 
more recently, carefully quanti tated in both animal 
models and humans [22--24]. Autoradiographic  stud- 
ies have provided evidence for lysosomal seques- 
tration of labeled gentamicin [5-7]. Cell fractionation 
studies have demonst ra ted  lysosomal localization of 
gentamicin after in vivo t rea tment  with low doses in 
animal models [4] and across a wide dose range 
in cultured fibroblasts [1,21. Inhibitory effects of 
aminoglycosides on lysosomal phospholipases have 
been documented  [25, 26] and increases in lvsosomal 
phospholipid levels have been shown to contribute 
to the tissue phospholipidosis seen in renal cortex 
after aminoglycoside t reatment  [27]. Aminogly-  
coside-induced increases and decreases in stability 
of lvsosomal membranes  have been reported 
[15, ,~8, 291 . 
However ,  the available data on lysosomal effects 
of aminoglycosides do not yet provide a full expla- 
nation of the pathogenesis of aminoglycoside- 
induced renal tubule cell injury for several reasons: 
(1) the mechanisms by which lvsosomal dysfunction 
results in acute lethal cell injury, despite much study 
in many models of injury, remain incompletely delin- 
eated and controversial  [30.31], (2) increases in size 
of lysosomes associated with increased uptake of 
slowly metabolized materials do not necessarily lead 
to ei ther lysosomal dysfunction or to cell injury as 
illustrated by the benign nature of the so-called 
osmotic nephropathies  resulting from administration 
of agents such as dextran [32], and (3) induction of 
a Ivsosomal phospholipidosis in the kidney as a result 
Subcellular distribution of gentamicin in kidney 1785 
of lysosomal sequestration of a cationic amphiphilic 
compound does not necessarily lead to acute lethal 
cell injury as illustrated by the effects of treatment 
with chlorphentermine. This cationic amphiphilic 
drug produces more widespread morphologic 
changes of lysosomal phospholipidosis in the kidney 
than do aminoglycosides but, to the extent that data 
are available, renal functional impairment is mild 
and acute lethal renal tubule cell injury is not promi- 
nent [33]. While certain properties of amino- 
glycosides may make them uniquely effective lyso- 
somal toxins, substantial data are available to 
support the importance of cellular loci in addition to 
lvsosomes as sites of aminoglycoside-induced renal 
tubular cell injury. Interactions of aminoglycosides 
with brush border membranes and mitochondria 
have been detailed with in vitro model systems [3]. 
Evidence for the in v ivo  occurrence of such inter- 
actions prior to the development of lethal cell injury 
has been reported [9, 10, 12]. Aminoglycoside inhi- 
bition of nonlysosomal phospholipases occurs 
[34, 35]. The phospholipidosis produced by amino- 
glycosides in the kidney is not necessarily limited to 
lysosomes [13]. A recent detailed reassessment of 
aminoglycoside uptake by radioautography has sug- 
gested the occurrence of an early cytoplasmic phase 
of aminoglycoside intracellular distribution [7]. 
To better understand the relationship between 
lysosomal and extralysosomal events in the cellular 
pathophysiology of aminoglycoside nephrotoxicity, 
it would be helpful to know more about the potential 
for gentamicin distribution intracellularly. The pre- 
sent study was designed to better ascertain the utility 
of subcellular fractionation procedures for obtaining 
this information under conditions of substantial but 
unequivocally, prelethal aminoglycoside-induced 
renal tubular cell injury. It has been stated that 
cellular fractionation studies after high or prolonged 
doses of aminogtycosides are fraught with difficulty 
[4 I, but no specific data have been reported to pro- 
vide a basis for further investigation or improvement 
of methodology. The present study provides such 
information, 
Prior subcellular fractionation studies of liver after 
treatment with cationic amphiphilic drugs which 
induced the formation of large numbers of myeloid 
bodies in hepatocytes have shown that these myeloid 
bodies can be isolated in enriched form, they have 
the enzymatic characteristics of lysosomes, they tend 
to equilibrate at lower gradient densities than do 
normal lysosomes, and they are the major intra- 
cellular sites of drug concentration [17--20]. Detailed 
studies of fibroblasts exposed to a range of con- 
centrations of gentamicin and other aminoglycoside 
antibiotics have demonstrated similar dose-depen- 
dent effects of the aminoglycosides on lysosomes 
[1, 2]. 
One important consideration in cell fractionation 
studies after in v ivo  treatment is the possibility of 
redistribution of drug during the fractionation pro- 
cedure. This is of particular importance for the 
aminoglycosides in view of their proclivity to bind to 
various subcellular membranes [11, 14-16]. Most of 
the available studies with the cationic amphiphilic 
drugs and aminoglycosides have not provided data 
on distribution of drug after in vitro exposure during 
subcellular fractionation. In the single study which 
carefully addressed this issue it was found that strep- 
tomycin exposure in vitro did not produce a pref- 
erential lysosomal drug distribution such as was seen 
after in v ivo  exposure to several aminoglycosides 
[1]. However, streptomycin is the least cationic of the 
commonly utilized aminoglycosides and, probably as 
a result of this, has the lowest in v ivo  uptake rate, 
the fewest documented subcellular effects in the 
kidney, and the least in v ivo  nephrotoxicity [3]. 
In contrast to the observations with streptomycin, 
appreciable in vitro binding of gcntamicin to a light 
microsomal fraction from renal cortex has been 
described but enzymatic characterization of ':his frac- 
tion was not provided and concomitant studies of the 
distribution of gentamicin after in v ivo  adminis- 
tration were not reported [14]. 
The present study compared the distribution of 
gentamicin on a discontinuous sucrose density gradi- 
ent 24 hr after four daily 100 mg/kg doses with the 
distribution of gentamicin added to the hom- 
ogenizing solution used for normal renal cortex so 
as to produce levels similar to those found in the 
treated animals. The four dose protocol has been 
used extensively in our laboratory in a number of 
studies of in v ivo  gentamicin nephrotoxicity. It 
reproducibly results in widespread but uniformly 
prelethal proximal renal tubule morphological and 
functional changes [9, 10], 
The gradient procedures utilized for the present 
studies were chosen, after evaluation of a variety of 
methods, to reproducibly separate subcellular organ- 
elles with the minimum number of steps, the least 
disruptive handling and without selectively losing 
and, thereby, failing to assess the contribution of any 
major subcellular component. As a result, individual 
subcellular elements are not nearly as purified as 
would result from procedures dedicated to isolating 
them uniquely. 
The main findings of the present study were that: 
(a) In both control and in v ivo  and in vitro gentamicin 
preparations a major localization of the activity of 
the lysosomal enzyme NAG occurred in a very light 
membrane fraction also enriched in the endoplasmic 
reticulum enzyme NADPH-cytochrome c reductase. 
(b) After in v ivo  gentamicin treatment the dis- 
tribution of gentamicin along the gradient also 
showed a major localization in the same light mem- 
brane fraction as NAG did and, within this gradient 
fraction, the distribution of gentamicin correlated 
very closely with the distribution of NAG.  This 
observation, thus, is apparently consistent with pre- 
vious reports on the behavior of lysosomes after 
treatment with cationic amphiphilic drugs or amino- 
glycosides in that lysosomes tended to migrate at 
lower densities and contained the drug [1,2, 17-20]. 
(c) However. when gentamicin was added in vitro to 
the homogenizing solution used for renal cortices 
from control rats to levels approximating the genta- 
micin levels seen after in v ivo  treatment, the dis- 
tribution of gentamicin on the gradient was very 
similar to that seen after in v ivo  treatment with 
respect to a major localization of gentamicin in the 
same light membrane fraction as NAG and a rela- 
tively close correlation of gentamicin with NAG 
within that fraction. In this regard, the results of 
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these studies of in vitro gentamicin addition are 
similar to those of the one previously reported study 
of exposure of subceltular membrane fragments [14] 
to gentamicin; however, the present study sub- 
stantially extends that observation by enzymatically 
defining the nature of the light membrane fraction 
showing preferential gentamicin localization. 
The data obtained in the present study are com- 
patible with several interpretations: 
(a) The similarity of gentamicin distribution after 
in u ivo  and in vitro exposure may be due to total 
disruption of lysosomes during homogenization of 
the renal cortex after in v ivo  gentamicin, Several 
observations argue against this as the only expla- 
nation for the findings: (1) the major features of 
enzyme distribution on the gradient in the present 
study were similar in control and gentamicin-treated 
rats, suggesting that substantial differences in organ- 
ellar integrity were not produced by the in v ivo  
gentamicin treatment as utilized. (2) The meth- 
odology for tissue homogenization used in this study 
was the same as that routinely described by other 
investigators [1, 2, 4, 17-20] and has, in our hands, 
produced highly functional mitochondria and highly 
enriched mitochondrial as well as heavy lysosome 
fractions by differential centrifugation. (3) Unsedi- 
mentable enzyme activity left in the supernatant 
layer after ultracentrifugation of the gradient (Fig. 
3) was as low as has been reported in the literature 
[1, 2, 4, 17-20]. Furthermore, the protein content of 
the supernatant fraction was no higher than that 
in any of the other subcelluar fractionation studies 
referenced in this paper which provided evaluable 
data for this parameter. We did not measure "free" 
as opposed to latent enzyme activities in our gradient 
fractions. Although "free" enzyme activity is a valu- 
able parameter for assessing lysosomal integrity, it 
may arise from unusually permeable as well as from 
severely damaged lysosomes and is, thus, a more 
equivocal measure of major lysosomal disruption 
than is unsedimentable activity. Furthermore, lyso- 
somal membrane changes contributing to increases 
in "free" enzyme activity may occur in v ivo  during 
gentamicin treatment as well as during hom- 
ogenization so that increased free levels do not 
necessarily mean that such changes are in vitro arti- 
facts. (4) Unsedimentable gentamicin was sig- 
nificantly higher with in vitro addition than after in 
v ivo treatment suggesting that gentamicin which was 
sequestered in v ivo  was not being totally released 
during subcellular fractionation. 
(b) The high levels of gentamicin in the light 
membrane fraction in association with the lysosomal 
enzyme NAG may indicate that concentrative uptake 
of gentamicin by Iysosomes can occur as a result of 
direct gentamicin lysosomal interactions without the 
requirement for adsorptive pinocytosis to the plasma 
membrane, the process which has been felt to 
account for most in v ivo  renal tubule cell uptake 
of gentamicin [3]. Such lysosomal sequestration of 
gentamicin upon direct exposure would be com- 
patible with results of recent autoradiographic stud- 
ies suggesting the occurrence of a cytoplasmic phase 
of gentamicin distribution acutely after renal tubule 
cell gentamicin uptake and prior to lysosomal seques- 
tration in t,ivo [7]. 
(c) The similarity between the distribution of 
gentamicin on the sucrose gradients after in v ivo and 
in vitro exposure may be due to a coincidence of two 
events. In v ivo  gentamicin may indeed be seques- 
tered in light lysosomes while in vitro gentamicin 
becomes bound to membrane surfaces rich in acidic 
phospholipids. We have shown previously that the 
light membrane fraction which contained the most 
gentamicin after in v ivo  and in vitro exposure in the 
present study is particularly rich in one of the major 
phospholipid binding sites for aminoglycosides. 
phosphatidylinositol [13]. Binding to phosphat- 
idylinositol does not, however, explain why, after in 
vivo  exposure, the association of gentamicin with a 
lysosomal enzyme, NAG, is closer than with the 
other enriched membrane bound enzyme in that 
fraction, NADPH-cytochrome c reductase. Fur- 
thermore, fractions slightly heavier than the mem- 
brane fraction which is most enriched in gentamicin 
also contain relatively high acidic phospholipid levels 
[13] without showing similar degrees of enrichment 
of gentamicin. 
The data in this study do not allow definitive 
evaluation of each of these hypotheses; however. 
with the phenomenon identified and reproducibly 
characterized it will be possible to design experi- 
ments to distinguish between the major mechanisms 
outlined. The available data do suggest that some 
caution must remain in attributing gentamicin renal 
tubule cell uptake exclusively to adsorptive pino- 
cytosis followed by sequestration within lvsosomes 
without opportunity to interact with intracellular 
structures. Though difficult and requiring careful 
interpretation, further studies of gentamicin dis- 
tribution during prolonged and high dose models 
of the type that ultimately lead to significant renal 
functional impairment are likely to yield useful infor- 
mation for understanding the cellular pathophysi- 
ology of gentamicin-induced renal tubular cell injury 
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